Bright Minds Biosciences (DRUG) to Release Quarterly Earnings on Wednesday

Key Points

• Bright Minds Biosciences (NASDAQ:DRUG) is set to report its Q3 2025 earnings on August 13th, with analysts anticipating a loss of ($0.59) per share.
• The company's previous quarterly earnings beat estimates, reporting ($0.29) EPS, which was better than the expected ($0.39).
• Currently, the average price target for Bright Minds Biosciences stands at $83.25, with most analysts rating the stock as a "Moderate Buy."

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) will likely be issuing its Q3 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.59) per share for the quarter.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.10. On average, analysts expect Bright Minds Biosciences to post $-1 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Bright Minds Biosciences Trading Up 11.6%

NASDAQ:DRUG traded up $4.02 on Friday, hitting $38.82. 164,381 shares of the stock were exchanged, compared to its average volume of 40,092. Bright Minds Biosciences has a fifty-two week low of $0.94 and a fifty-two week high of $79.02. The stock has a market cap of $273.29 million, a PE ratio of -107.83 and a beta of -6.07. The stock has a fifty day moving average of $28.86 and a 200-day moving average of $32.11.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on DRUG shares. Wall Street Zen lowered Bright Minds Biosciences from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Cantor Fitzgerald reissued an "overweight" rating on shares of Bright Minds Biosciences in a research report on Wednesday, July 2nd. Cowen started coverage on Bright Minds Biosciences in a research report on Tuesday, May 13th. They set a "buy" rating on the stock. Chardan Capital reissued a "buy" rating and set a $80.00 price target on shares of Bright Minds Biosciences in a research report on Wednesday, May 21st. Finally, TD Cowen started coverage on Bright Minds Biosciences in a research report on Tuesday, May 13th. They set a "buy" rating on the stock. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $83.25.

Institutional Investors Weigh In On Bright Minds Biosciences

Hedge funds have recently bought and sold shares of the business. Millennium Management LLC grew its stake in Bright Minds Biosciences by 376.9% during the 1st quarter. Millennium Management LLC now owns 192,557 shares of the company's stock valued at $6,946,000 after purchasing an additional 152,178 shares in the last quarter. Geode Capital Management LLC acquired a new stake in Bright Minds Biosciences during the 2nd quarter valued at approximately $1,502,000. Finally, Goldman Sachs Group Inc. acquired a new stake in Bright Minds Biosciences during the 1st quarter valued at approximately $802,000. Institutional investors and hedge funds own 40.52% of the company's stock.

About Bright Minds Biosciences

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.